Sfoglia per Autore
Should CYP2D6 be genotyped when treating with tamoxifen?
2016-01-01 DEL RE, Marzia; Rofi, Eleonora; Citi, Valentina; Fidilio, Leonardo; Danesi, Romano
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
2016-01-01 DEL RE, Marzia; Citi, Valentina; Crucitta, Stefania; Rofi, Eleonora; Belcari, Francesca; Van Schaik, R. H.; Danesi, Romano
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World
2017-01-01 Di Paolo, Antonello; Del Re, Marzia; Arrigoni, Elena; Di Desidero, Teresa; Rofi, Eleonora; Danesi, Romano; Bocci, Guido
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
2017-01-01 Del Re, Marzia; Rofi, Eleonora; Restante, Giuliana; Crucitta, Stefania; Arrigoni, Elena; Fogli, Stefano; Di Maio, Massimo; Petrini, Iacopo; Danesi, Romano
Should CYP2D6 be genotyped when treating with tamoxifen? [Letter in reply]
2017-01-01 Del Re, Marzia; Rofi, Eleonora; Citi, Valentina; Fidilio, Leonardo; Danesi, Romano
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase.
2017-01-01 Del Re, M; Restante, G; Di Paolo, A; Crucitta, S; Rofi, E; Danesi, R.
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment
2017-01-01 Bordi, Paola; Tiseo, Marcello; Rofi, Eleonora; Petrini, Iacopo; Restante, Giuliana; Danesi, Romano; DEL RE, Marzia
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
2017-01-01 DEL RE, Marzia; Vivaldi, Caterina; Rofi, Eleonora; Vasile, Enrico; Miccoli, Mario; Caparello, Chiara; D'Arienzo, Pd; Fornaro, L; Falcone, Alfredo; Danesi, Romano
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment
2017-01-01 Del Re, M; Bordi, P; Petrini, I; Rofi, Eleonora; Mazzoni, Fabrizia; Belluomini, L; Vasile, Enrico; Restante, Giuliana; Di Costanzo, F; Falcone, A; Frassoldati, A; van Schaik, Rhn; Steendam, Cmj; Chella, A; Tiseo, M; Morganti, R; Danesi, R.
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer
2017-01-01 Del Re, M; Vivaldi, C; Rofi, E; Vasile, E; Miccoli, M; Caparello, C; D'Arienzo, P; Fornaro, L; Falcone, A; Danesi, R
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells
2018-01-01 Del Re, Marzia; Arrigoni, Elena; Restante, Giuliana; Passaro, Antonio; Rofi, Eleonora; Crucitta, Stefania; De Marinis, Filippo; Di Paolo, Antonello; Danesi, Romano
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
2018-01-01 DEL RE, Marzia; Marconcini, Riccardo; Pasquini, Giulia; Rofi, Eleonora; Vivaldi, Caterina; Bloise, Francesco; Restante, Giuliana; Arrigoni, Elena; Caparello, Chiara; Bianco, MARIA GRAZIA; Crucitta, Stefania; Petrini, Iacopo; Vasile, Enrico; Falcone, Alfredo; Danesi, Romano
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment
2018-01-01 Del Re, Marzia; Crucitta, Stefania; Restante, Giuliana; Rofi, Eleonora; Arrigoni, Elena; Biasco, Elisa; Sbrana, Andrea; Coppi, Erika; Galli, Luca; Bracarda, Sergio; Santini, Daniele; Danesi, Romano
Clinical pharmacology of intravitreal anti-VEGF drugs
2018-01-01 Fogli, Stefano; Del Re, Marzia; Rofi, Eleonora; Posarelli, Chiara; Figus, Michele; Danesi, Romano
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680â7
2018-01-01 Del Re, Marzia; Biasco, Elisa; Crucitta, Stefania; Derosa, Lisa; Rofi, Eleonora; Orlandini, Cinzia; Miccoli, Mario; Galli, Luca; Falcone, Alfredo; Jenster, Guido W.; van Schaik, Ron H.; Danesi, Romano
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment
2018-01-01 Arrigoni, Elena; Del Re, Marzia; Galimberti, Sara; Restante, Giuliana; Rofi, Eleonora; Crucitta, Stefania; Baratè, Claudia; Petrini, Mario; Danesi, Romano; Di Paolo, Antonello
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy
2018-01-01 Minari, R.; Bordi, P.; Del Re, M.; Facchinetti, F.; Mazzoni, F.; Barbieri, F.; Camerini, A.; Comin, C. E.; Gnetti, L.; Azzoni, C.; Nizzoli, R.; Bortesi, B.; Rofi, E.; Petreni, P.; Campanini, N.; Rossi, G.; Danesi, R.; Tiseo, M.
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance
2018-01-01 Fogli, Stefano; Polini, Beatrice; DEL RE, Marzia; Petrini, Iacopo; Passaro, Antonio; Crucitta, Stefania; Rofi, Eleonora; Danesi, Romano
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response
2018-01-01 Del Re, Marzia; Bordi, Paola; Rofi, Eleonora; Restante, Giuliana; Valleggi, Simona; Minari, Roberta; Crucitta, Stefania; Arrigoni, Elena; Chella, Antonio; Morganti, Riccardo; Tiseo, Marcello; Petrini, Iacopo; Danesi, Romano
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring
2019-01-01 Pasqualetti, Francesco; Restante, Giuliana; Gonnelli, Alessandra; Rofi, Eleonora; Molinari, Alessandro; Crucitta, Stefania; Paiar, Fabiola; Rudà, Roberta; Danesi, Romano; Soffietti, Riccardo; Del Re, Marzia
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Should CYP2D6 be genotyped when treating with tamoxifen? | 1-gen-2016 | DEL RE, Marzia; Rofi, Eleonora; Citi, Valentina; Fidilio, Leonardo; Danesi, Romano | |
| Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? | 1-gen-2016 | DEL RE, Marzia; Citi, Valentina; Crucitta, Stefania; Rofi, Eleonora; Belcari, Francesca; Van Schaik, R. H.; Danesi, Romano | |
| Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World | 1-gen-2017 | Di Paolo, Antonello; Del Re, Marzia; Arrigoni, Elena; Di Desidero, Teresa; Rofi, Eleonora; Danesi, Romano; Bocci, Guido | |
| Implications of KRAS mutations in acquired resistance to treatment in NSCLC | 1-gen-2017 | Del Re, Marzia; Rofi, Eleonora; Restante, Giuliana; Crucitta, Stefania; Arrigoni, Elena; Fogli, Stefano; Di Maio, Massimo; Petrini, Iacopo; Danesi, Romano | |
| Should CYP2D6 be genotyped when treating with tamoxifen? [Letter in reply] | 1-gen-2017 | Del Re, Marzia; Rofi, Eleonora; Citi, Valentina; Fidilio, Leonardo; Danesi, Romano | |
| Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. | 1-gen-2017 | Del Re, M; Restante, G; Di Paolo, A; Crucitta, S; Rofi, E; Danesi, R. | |
| Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment | 1-gen-2017 | Bordi, Paola; Tiseo, Marcello; Rofi, Eleonora; Petrini, Iacopo; Restante, Giuliana; Danesi, Romano; DEL RE, Marzia | |
| Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer | 1-gen-2017 | DEL RE, Marzia; Vivaldi, Caterina; Rofi, Eleonora; Vasile, Enrico; Miccoli, Mario; Caparello, Chiara; D'Arienzo, Pd; Fornaro, L; Falcone, Alfredo; Danesi, Romano | |
| Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment | 1-gen-2017 | Del Re, M; Bordi, P; Petrini, I; Rofi, Eleonora; Mazzoni, Fabrizia; Belluomini, L; Vasile, Enrico; Restante, Giuliana; Di Costanzo, F; Falcone, A; Frassoldati, A; van Schaik, Rhn; Steendam, Cmj; Chella, A; Tiseo, M; Morganti, R; Danesi, R. | |
| Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer | 1-gen-2017 | Del Re, M; Vivaldi, C; Rofi, E; Vasile, E; Miccoli, M; Caparello, C; D'Arienzo, P; Fornaro, L; Falcone, A; Danesi, R | |
| Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells | 1-gen-2018 | Del Re, Marzia; Arrigoni, Elena; Restante, Giuliana; Passaro, Antonio; Rofi, Eleonora; Crucitta, Stefania; De Marinis, Filippo; Di Paolo, Antonello; Danesi, Romano | |
| PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC | 1-gen-2018 | DEL RE, Marzia; Marconcini, Riccardo; Pasquini, Giulia; Rofi, Eleonora; Vivaldi, Caterina; Bloise, Francesco; Restante, Giuliana; Arrigoni, Elena; Caparello, Chiara; Bianco, MARIA GRAZIA; Crucitta, Stefania; Petrini, Iacopo; Vasile, Enrico; Falcone, Alfredo; Danesi, Romano | |
| Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment | 1-gen-2018 | Del Re, Marzia; Crucitta, Stefania; Restante, Giuliana; Rofi, Eleonora; Arrigoni, Elena; Biasco, Elisa; Sbrana, Andrea; Coppi, Erika; Galli, Luca; Bracarda, Sergio; Santini, Daniele; Danesi, Romano | |
| Clinical pharmacology of intravitreal anti-VEGF drugs | 1-gen-2018 | Fogli, Stefano; Del Re, Marzia; Rofi, Eleonora; Posarelli, Chiara; Figus, Michele; Danesi, Romano | |
| Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680â7 | 1-gen-2018 | Del Re, Marzia; Biasco, Elisa; Crucitta, Stefania; Derosa, Lisa; Rofi, Eleonora; Orlandini, Cinzia; Miccoli, Mario; Galli, Luca; Falcone, Alfredo; Jenster, Guido W.; van Schaik, Ron H.; Danesi, Romano | |
| Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment | 1-gen-2018 | Arrigoni, Elena; Del Re, Marzia; Galimberti, Sara; Restante, Giuliana; Rofi, Eleonora; Crucitta, Stefania; Baratè, Claudia; Petrini, Mario; Danesi, Romano; Di Paolo, Antonello | |
| Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy | 1-gen-2018 | Minari, R.; Bordi, P.; Del Re, M.; Facchinetti, F.; Mazzoni, F.; Barbieri, F.; Camerini, A.; Comin, C. E.; Gnetti, L.; Azzoni, C.; Nizzoli, R.; Bortesi, B.; Rofi, E.; Petreni, P.; Campanini, N.; Rossi, G.; Danesi, R.; Tiseo, M. | |
| EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance | 1-gen-2018 | Fogli, Stefano; Polini, Beatrice; DEL RE, Marzia; Petrini, Iacopo; Passaro, Antonio; Crucitta, Stefania; Rofi, Eleonora; Danesi, Romano | |
| The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response | 1-gen-2018 | Del Re, Marzia; Bordi, Paola; Rofi, Eleonora; Restante, Giuliana; Valleggi, Simona; Minari, Roberta; Crucitta, Stefania; Arrigoni, Elena; Chella, Antonio; Morganti, Riccardo; Tiseo, Marcello; Petrini, Iacopo; Danesi, Romano | |
| Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring | 1-gen-2019 | Pasqualetti, Francesco; Restante, Giuliana; Gonnelli, Alessandra; Rofi, Eleonora; Molinari, Alessandro; Crucitta, Stefania; Paiar, Fabiola; Rudà, Roberta; Danesi, Romano; Soffietti, Riccardo; Del Re, Marzia |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile